Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence

Emanuele Bertaglia¹, Benjamin Blank², Carina Blomström-Lundqvist³, Axel Brandes⁴,⁵, Nuno Cabanelas⁶, G.-Andrei Dan⁷, Wolfgang Dichtl⁸, Andreas Goette²,⁹, Joris R. de Groot¹⁰, Andrzej Lubinski¹¹, Eloi Marijon¹², Béla Merkely¹³, Lluis Mont¹⁴, Christopher Piorkowski¹⁵, Andrea Sarkozy¹⁶, Neil Sulke¹⁷, Panos Vardas¹⁸, Vasil Velchev¹⁹, Dan Wichterle²⁰, and Paulus Kirchhof²,²¹*

¹Department of Cardiac, Vascular and Thoracic Sciences, Azienda Ospedaliera, Padua, Italy; ²Atrial Fibrillation NETwork (AFNET), Muenster, Germany; ³Department of Medical Science, Uppsala University, Uppsala, Sweden; ⁴Department of Clinical Research, University of Southern Denmark, Odense, Denmark; ⁵Department of Cardiology, Odense University Hospital, Odense, Denmark; ⁶Arrhythmias Unit of Cardiology Department, Hospital Prof. Dr. Fernando Fonseca, Amadora-Sintra, Portugal; ⁷Colentina University Hospital, Medicine University “Carol Davila”, Bucharest, Romania; ⁸University Hospital of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria; ⁹St. Vincenz Hospital Paderborn, Cardiology and Intensive Care Medicine, Paderborn, Germany; ¹⁰Department of Cardiology, Heart Center, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; ¹¹Department of Interventional Cardiology and Arrhythmias, Medical University of Lodz, Lodz, Poland; ¹²Cardiac Electrophysiology Section, European Georges Pompidou Hospital, Paris, France; ¹³Heart and Vascular Center, Semmelweis University Budapest, Budapest, Hungary; ¹⁴Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Catalunya, Spain; ¹⁵Herzzentrum Dresden GmbH, Universitätsklinikum, Dresden, Germany; ¹⁶Université Libre de Bruxelles, Brussels, Belgium; ¹⁷Eastbourne District General Hospital, Eastbourne, UK; ¹⁸Heart Sector, Hygeia Group Hospitals, Athens, Greece; ¹⁹Cardiology Clinic, St. Anna University Hospital, Medical University Sofia, Sofia, Bulgaria; ²⁰Institute for Clinical and Experimental Medicine, Prague, Czech Republic; and ²¹Institute of Cardiovascular Sciences, University of Birmingham, UHB and Sandwell & West Birmingham Hospitals NHS Trusts, IBR 126a, Wolfson Drive, Birmingham B15 2TT, UK

Received 18 March 2019; editorial decision 26 May 2019; accepted 15 July 2019; online publish-ahead-of-print 3 August 2019

Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring, e.g. by pacemakers or defibrillators. It is unclear whether the presence of these arrhythmias has therapeutic consequences. We sought to summarize evidence on the prevalence of atrial high-rate episodes (AHREs) and their impact on risk of stroke. We performed a comprehensive, tabulated review of published literature on the prevalence of AHRE. In patients with AHRE, but without atrial fibrillation (AF), we reviewed the stroke risk and the potential risk/benefit of oral anticoagulation. Atrial high-rate episodes are found in 10–30% of AF-free patients. Presence of AHRE slightly increases stroke risk (0.8% to 1%/year) compared with patients without AHRE. Atrial high-rate episode of longer duration (e.g. those >24 h) could be associated with a higher stroke risk. Oral anticoagulation has the potential to reduce stroke risk in patients with AHRE but is associated with a rate of major bleeding of 2%/year. Oral anticoagulation is not effective in patients with heart failure or survivors of a stroke without AF. It remains unclear whether anticoagulation is effective and safe in patients with AHRE. Atrial high-rate episodes are common and confer a slight increase in stroke risk. There is true equipoise on the best way to reduce stroke risk in patients with AHRE. Two ongoing trials (NOAH-AFNET 6 and ARTESiA) will provide much-needed information on the effectiveness and safety of oral anticoagulation using non-vitamin K antagonist oral anticoagulants in patients with AHRE.

Keywords

Atrial fibrillation • Atrial high-rate episodes • Pacemaker • Stroke • Anticoagulation • Continuous monitoring

* Corresponding author. Tel: +44 121 414 7042. E-mail address: p.kirchhof@bham.ac.uk

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

The increased use of cardiac implantable electronic devices (CIED) and their technical ability to monitor atrial rhythm and to identify even very short episodes of atrial arrhythmias has transformed our understanding of these events in the last 10–15 years. Having an atrial lead implanted, CIED can detect episodes of atrial tachyarrhythmias including atrial tachycardia, atrial flutter, and atrial fibrillation (AF). These episodes, which are commonly asymptomatic and only detected through long-term continuous rhythm monitoring by a CIED, are described as atrial high-rate episodes (AHREs) and must be distinguished from asymptomatic episodes of paroxysmal AF, which are diagnosed through surface electrocardiographic methods.1–4: Some AHRE do not represent true atrial tachyarrhythmias, but reflect artefacts.5 In addition, the biological relevance of very rare AHRE, which will usually not be detected by occasional electrocardiograms (ECGs), remains unknown.

Here, we provide a comprehensive review of the prevalence of AHRE, their impact on stroke risk and current implications for management. While other have used the term ‘sub-clinical AF’, we use AHRE in this review, partially reflecting the diagnostic uncertainty, the high prevalence of AHRE compared with ECG-documented AF, and their spurious association with overt AF and with AF-related outcomes.

Prevalence of atrial high-rate episodes in patients undergoing continuous atrial rhythm monitoring

Atrial high-rate episodes have been reported in several large observational studies with different design, cohort size, patient characteristics, duration of follow-up, detection algorithms, and definition of AHRE in terms of atrial rate and duration (Table 1). Most of these studies included unselected patients with common indications for pacemaker or implantable cardioverter-defibrillator,6–15 while others analysed populations with heart failure or risk factors for stroke.16–23 Most studies used an atrial rate limit of >175 or >180 to define an AHRE,6,11,12,16–18,20 while a few others used atrial rates that were even higher.7,9,10,12,14,17–19,22,23 Atrial high-rate episodes were reported in 10% in the SAFE registry and in 70% in the analysis of data from the Veterans Administration Health Care System (Table 1). Importantly, studies including patients with the clinical diagnosis AF, which per se have a higher frequency of atrial arrhythmias, found AHRE in 40–70%.16–9,11,13,16,20,21,23 Studies excluding patients with known AF have found AHRE in 10–30% of patients % (Figure 1).10,12,14,17–19,22,23

The minimal duration of AHRE varied from three premature atrial complexes—much below the threshold for a sustained atrial arrhythmia in the view of most experts—in the RATE Registry to up to 14 min in the pooled analysis from the HOME Care and EVEREST trials.15,20 with the majority of studies using an episode duration longer than 5–6 min to define AHRE.7,9,10,12,14,17–19,22,23 This duration seems to be a ‘diagnostic sweet spot’ that allows most algorithms detecting AHRE to distinguish artefacts from true atrial arrhythmias. This duration has not been selected based on biological relevance (e.g. association with stroke risk). There is a clear relation between the detection of AHRE and the duration of monitoring, e.g. illustrated in the ASSERT trial that found AHRE in 10% of patients within the first 3 months after enrolment, and in an additional 24.5% during the subsequent mean follow-up of 2.5 years.19,24

The high AHRE detection rates spurred discussion whether these rates are generalizable, e.g. reflecting that these patients all had arrhythmias requiring a CIED which may also create a substrate for AHRE,12,25 and potentially a proarrhythmic effect in the first few weeks after implantation of a new atrial lead.12,26 Several studies using subcutaneous implantable loop recorders (ILRs) have largely refuted these considerations, at least in patients with stroke risk factors. These devices detect QRS complexes and determine AHRE using similar algorithms based on ventricular rate and its regularity.27,28 Implantation of an ILR in stroke survivors, often after usual work-up for AF including Holter monitoring, found AHRE in 4–34% of patients, depending on monitoring duration and patient characteristics (Table 2).29–40 Implantable loop recorders also detect AHREs in 21–58% of patients with cardiovascular conditions, but without an indication for rhythm monitoring (Table 3).41–45 i.e. with comparable rates as in pacemaker populations. Thus, these data suggest that AHRE are common in patients with cardiovascular conditions undergoing long-term continuous monitoring of atrial rhythm.

Patients with atrial fibrillation, including those with paroxysmal atrial fibrillation, are at sufficient risk for cardioembolic stroke to benefit from oral anticoagulation for stroke prevention

Atrial fibrillation in rheumatic heart disease was recognized as a factor that predisposes to systemic embolism in 1951.46 Left atrial emboli causing ischaemic stroke were described a decade later.47 In the Framingham Heart Study, AF was associated with a five-fold long-term increased risk of stroke.48,49 Prospective randomized studies from the late 1980s reported a dramatic and highly significant reduction in stroke in patients with AF treated with warfarin. The randomized AFASAK,50 SPAF51 and BAATAp52 studies were among the first to demonstrate that dose-adjusted warfarin prevented strokes effectively in patients with AF, confirmed in a later meta-analysis.53

Until recently, the risk of thromboembolism has been considered to be independent of AF type.54–57 Previous systematic reviews of risk factors for stroke in AF patients have not identified AF type as an important prognostic risk factor for thromboembolism.58–60 Atrial fibrillation stroke risk prediction models have, in general, not included AF type61–64 perhaps because of absence of AF pattern information in hospitalization/discharge databases that were used for their derivation and validation. This consensus of risk equivalence between AF patterns is reflected by Class I and IIa recommendations in current European55 and North American54 guidelines.

Vanasse et al.65 pooled the data on aspirin-treated patients (n = 6573) from the ACTIVE-A and AVERROES trials. Atrial fibrillation pattern was a strong independent predictor of risk for...
Figure 1: Percentage of AHRE in patients with (left panel) and without (right panel) known AF. AF, atrial fibrillation; AHRE, atrial high-rate episode.

Table 1: Incidence of CIED-detected AHRE

| Study                  | Number of patients | Mean age (years) | % male | Duration of follow-up | Definition of AHRE                                                                 | Patients with AHRE |
|------------------------|--------------------|------------------|--------|------------------------|---------------------------------------------------------------------------------|--------------------|
| AIDA (1998)            | 617                | 70 ± 11          | 62%    | 28 days                | >1 min (the AIDA algorithm)                                                       | 179/354 (50.6%)    |
| Gillis et al. (2002)   | 231                | 70 ± 12          | 52%    | 718 ± 383 days         | Atrial rate >180 b.p.m. for >1 min; sustained AF >250 b.p.m. for >1 min          | 126/231 (54.5%)    |
| MOST (2003)            | 312                | 74               | 45%    | Median 27 months       | Atrial rate >220 b.p.m. for >5 min                                               | 160/312 (51.3%)    |
| Tse et al. (2005)      | 226                | 72 ± 10 in patients with detected AF; 70 ± 10 in patients without detected AF | 39%    | 84 ± 16 months         | Any AT detected by the device                                                     | 99/226 (43.8%)     |
| Capucci et al. (2005)  | 725                | 71 ± 11          | 50%    | Median 22 months (16–30) | AF >5 min; AF >1 day                                                              | 76.2%; 56.3%       |
| Cheung et al. (2006)   | 262                | 74 ± 12          | 54%    | 596 ± 344 days         | AHRE ≥5 min                                                                      | 77/262 (29%)       |
| A-HIRATE (2007)        | 427                | 75 ± 9           | 56%    | 24 months              | Atrial rate >180 b.p.m. for ≥1 min                                               | 53.8% in patients without previous AT; 88.6% in patients with previous AT |
| SAFE registry (2008)   | 1482               | 74 ± 12          | 56%    | Median 349 ± 147 days  | Atrial rate ≥180 b.p.m. for ≥5 min                                               | 150/1482 (10.1%)   |
| TRENDS (2009)          | 2486               | 71 ± 11          | 66.4%  | Median 1.4 years (0.1–3.3) | Atrial rate ≥175 b.p.m. for ≥20 s                                                 | 1389/2486 (55.9%)  |

Continued
embolic event (ischaemic or unspecified stroke or systemic embolism). The ACTIVE-W trial found a trend towards higher stroke (and systemic embolism) rates in persistent/permanent compared with paroxysmal AF in non-anticoagulated patients but not in warfarintreated patients.57 Similarly, the data from Friberg et al.66 did not show a significant overall difference in stroke rates according to AF pattern, but found an increase in ischaemic stroke in the subgroup of non-anticoagulated patients with permanent compared with

| Study            | Number of patients | Mean age (years) | % male | Duration of follow-up | Definition of AHRE                                                                 | Patients with AHRE |
|------------------|--------------------|------------------|--------|-----------------------|-----------------------------------------------------------------------------------|--------------------|
| TRENDS (2010)    | 163                | 74.0 ± 9.1 in patients with AHRE; 72.8 ± 9.9 in patients without AHRE | 71.1% in patients with AHRE; 62.7% in patients without AHRE | 1.1 ± 0.7 years                                                                  | Atrial rate > 175 b.p.m. for ≥5 min                                             | 45/163 (27.6%)     |
| TRENDS (2012)    | 1368               | 70.2 ± 11.8      | 66.2%  | 1.1 ± 0.7 years       | Atrial rate > 175 b.p.m. for ≥5 min                                              | 416/1368 (30.4%)   |
| ASSERT (2012)    | 2580               | 77 ± 7 in patients with AHRE; 76 ± 7 in patients without AHRE | 56.3% in patients with AHRE; 58.6% in patients without AHRE | Mean 2.5 years                                                                  | Atrial rate ≥ 190 b.p.m. for >6 min; all episodes confirmed by manual expert review of electrograms | 261/2580 (10.1%); |
|                  |                    |                  |        |                       |                                                                                   | 223/560 (39.8%);   |
| Shanmugam et al. (2012) | 560              | 66 ± 10          | 77.4%  | Median 370 days (253–390) | Atrial rate > 180 b.p.m. for ≥14 min                                             | 126/382 without history of AF, 97/178 with history of AF |
| Healey et al. (2013) | 445              | 74.3 ± 13.7 in patients with AHRE; 71.7 ± 14.4 in patients without AHRE | 58% in patients with AHRE; 59% in patients without AHRE | 51.5 ± 39.7 months                                                                  | Any PM detected AF (manufacturer-specific nominal settings for AF detection)       | 246/445 (55.3%)   |
| Gonzalez et al. (2014) | 224              | 74 ± 12          | 53%    | 6 months after PM implantation | Any device-detected AHRE ≥ 5 min                                                   | 39/224 (17.4%)     |
| IMPACT (2015)    | 2718               | Median 64.4      | 73.7%  | Median 701 days       | Atrial rate ≥ 200 b.p.m. for >6 of 48 atrial beats                                | 945/2718 (34.8%)   |
| Witt et al. (2015) | 394               | Median 67 years (59–74) | 74%    | Median 4.2 years (2.5–6.6) | Manufacturer-specific nominal settings for AF detection; AHREs >6 min             | 79/394 (20.0%)     |
| Turakhia et al. (2015) | 187              | 68 ± 8.4         | 99.5%  | 120 days              | AF ≥ 6 min                                                                       | 70.1% (26.2% ≥6 min of AF; 24.6% ≥1 h of AF; 19.3% ≥5.5 h of AF)               |
| RATE Registry (2016) | 5379             | 73.6 ± 11.8 in patients with PM; 64.5 ± 12.6 in patients with ICD | 54.1% with PM; 72.4% with ICD | Median 22.9 months                                                                  | >3 premature atrial complexes                                                    | 145/300 (48%) with PM and 155/300 (52%) with ICD of the representative random sample studied |
Table 2  Incidence of ILR-detected subclinical AF in patients with cryptogenic stroke or transient ischaemic attack

| Study                | Number of patients included | Mean age (years) | % male | Mean CHA2DS2-VASc score | Duration of follow-up | Definition of AHRE | Patients with AHRE | Time to first AHRE episode |
|----------------------|----------------------------|------------------|--------|-------------------------|-----------------------|--------------------|---------------------|-----------------------------|
| Dion et al. (2010)   | 24                         | 49 ± 13.6        | 62.5%  | NR                      | Mean 14.5 months     | Ventricular rate >165 b.p.m. for >32 complexes | 1/24 (4.2%) with AF <30 s | NR                          |
| Cotter et al. (2013) | 51                         | 51.5 ± 13.9      | 54.9%  | Median 3 (2–4)          | Mean 229 ± 112 days AF >2 min in patients without AHRE | Median 397 days (337–504) AF >2 min in patients without AHRE; median 312 days (242–397) with AHRE | 13/51 (25.5%) | Median 48 days (0–154) |
| Ritter et al. (2013) | 60                         | Median 63 (48.5–72.0) | 56.7%  | Median 4 (3–5) without AHRE; median 4 (3–5) with AHRE | Median 3 without AHRE; median 4 with AHRE | Median 3 without AHRE; median 4 with AHRE | 10/60 (16.7%) | Median 64 days (1–556) |
| Etgen et al. (2013)  | 22                         | 60.0 without AF; 65.8 with AF | 43.8%  | without AF; 66.7% with AF | NR | 12 months AF >6 min | 6/22 (27.3%) | Mean 152.8 |
| Rojo-Martinez et al. (2013) | 101 | 67 | 46.5% | NR | 281 ± 212 days AF >2 min | 34/101 (33.7%) | Median 102 days (26–240) |
| SURPRISE (2014)      | 85                         | 54.0 without AF; 66.9 with AF | 58.0%  | without AF; 44.4% with AF | Median 3 without AHRE; median 4 with AHRE | Median 3 without AHRE; median 4 with AHRE | 18/85 (20.7%) | 109 ± 48 days |
| CRYSTAL AF (2014)    | 441 (208 ICM)              | 61.5 ± 11.3      | 63.5%  | NR                      | 12 months AF >2 min | 8.9% at 6 months; 12.4% at 12 months | Median 41 days (14–84) |
| CRYSTAL AF (2016)    | 48 (24 ICM)?               | 61.6 ± 11.4      | ?      | NR                      | 36 months AF >2 min | 30% | ? |
| Poli et al. (2016)   | 74                         | 66.4 ± 12.5      | 47%    | Median 5 (4–6)          | 12 months AF >2 min | 21/74 (28.4%) at 6 months; 25/74 (33.8%) at 12 months | 105 ± 135 days |
| Israel et al. (2017) | 123                        | 65.0 ± 9.4       | 60.2%  | 4.5 ± 1.3               | 12.7 ± 5.5 months AF >2 min | 29/123 (23.6%) | Average 3.6 months |
| Reinke et al. (2018) | 105                        | 64.4 ± 12.6      | 56.2%  | Median 4 (3–4)          | ? | AF >2 min | 19/105 (18%) | Median 217 days (72.5–338) |
| Pedersen et al. (2018) | 105                   | Median 65.4 (27.1–80.8) | 45.7%  | Median 4 (2–7)          | Median 381 days (371–390) AF >2 min | 7/105 (6.7%) | Median 21 days (5–146) |

AF, atrial fibrillation; AFL, atrial flutter; AHRE, atrial high-rate episode; ILR, implantable loop recorders; ICM, intracardiac monitor; NR, not recorded.

Table 3  Incidence of ILR-detected subclinical AF in patients at high risk of stroke

| Study                | Number of patients | Mean age (years) | % male | Duration of follow-up | Definition of AHRE | Patients with AHRE | Time to first AHRE |
|----------------------|--------------------|------------------|--------|-----------------------|--------------------|---------------------|-------------------|
| ASSERT-II (2017)     | 273                | 73.9 ± 6.2       | 65.6%  | 16.3 ± 3.8 months   | AF including AFL and AT >5 min | 90/256 (35.2%) | 5.1 ± 5.5 months |
| REVEAL AF (2017)     | 446                | 71.5 ± 9.9       | 52.3%  | 22.5 ± 7.7 months   | AF ≥6 min          | 29.3% at 18 months; 6.2%; 20.4%; 27.1%; 33.6%; and 40.0% at 1, 6, 12, 24, and 30 months | Median 123 days (41–330) |
| PREDATE AF (2017)    | 245                | 74.3 ± 7.7       | 58.8%  | 18 months; mean follow-up 451 ± 165 days | AF ≥6 min | 55/245 (22.4%) | 141.3 ± 139.5 days |
| Philippien et al. (2017) | 82 | 71 ± 4.0       | 63%    | Median 588 days (453–712) | AF ≥2 min | 17/82 (20.7%); 14/82 (17%); 25/82 (30%) | Median 91 days (41–251) |
| Romanov et al. (2018) | 50                | 57.8 ± 8.3       | 88%    | ≥24 months            | AF ≥2 min | 29/50 (58%) at 24 months; 16%; 40%; 50%; and 54% at 3, 6, 12, and 18 months | Median 4.8 months |

AF, atrial fibrillation; AFL, atrial flutter; AHRE, atrial high-rate episode; ILR, implantable loop recorders.
paroxysmal AF. Recent trials in anticoagulated AF patients reported lower stroke rates in paroxysmal vs. non-paroxysmal AF patients (SPORTIF, ARISTOTLE, and ENGAGE-AF). A meta-analysis combining data from >95,000 patients appears to confirm that stroke risk may be slightly lower in patients with paroxysmal AF compared with those with chronic AF.

Patients at high stroke risk without atrial fibrillation do not benefit from oral anticoagulation

Oral anticoagulation using either vitamin K antagonists such as warfarin or non-vitamin K antagonist oral anticoagulants (NOACs) has been tested in several conditions predisposing for stroke other than AF usually without evidence for effectiveness.

Anticoagulants in survivors of a stroke without atrial fibrillation

Conducted almost 20 years ago, the WARSS trial could not detect a clinical benefit of warfarin [target international normalized ratio (INR) 1.4–2.8] over 325 mg aspirin per day after a non-cardioembolic ischaemic stroke in patients without AF within 2 years. In patients with a recent embolic stroke of undetermined source, the NAVIGATE ESUS trial has been stopped in 2017 due to no efficacy improvement of 15 mg rivaroxaban over 100 mg aspirin daily, with an increased risk of bleeding in patients randomized to rivaroxaban. A similar trial with dabigatran, the RESPECT ESUS study, similarly reported no reduction in stroke rates in patients randomized to dabigatran, with increased clinically relevant major bleedings compared to aspirin.

Anticoagulants in patients with other neurological disorders

The CADISS trial tested warfarin vs. aspirin in patients with symptomatic carotid and vertebral artery dissection. No difference was detected between oral anticoagulation or single antiplatelet treatment. The WASID trial compared warfarin (target INR 2.0–3.0) with high-dose aspirin (1300 mg per day) in patients with transient ischaemic attack or stroke caused by a 50–99% stenosis of a major intracranial artery. This study was stopped prematurely after 569 patients because of a significantly higher bleeding rate without any benefit in the warfarin arm.

Anticoagulants in patients with heart failure, but without atrial fibrillation

The WARCEF trial showed no difference between long-term warfarin and aspirin treatment in 2305 patients with a left ventricular ejection fraction below 35% and sinus rhythm. The primary composite endpoint (ischaemic stroke, intracerebral haemorrhage, and death from any cause) comprised 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group. COMMANDER-HF confirmed that rivaroxaban, albeit at a lower dose than the dose approved for stroke prevention in AF, was not effective in prevention of strokes compared with no anticoagulation in a similar heart failure population.

Risk of bleeding in patients treated with oral anticoagulants

The benefit of oral anticoagulation in patients with AF can so far only be achieved by exposing patients to an increased bleeding risk, but the bleeding rate on NOACs is still important (ca. 2% per year of exposure), both in clinical trials and in patients exposed to NOACs under routine care conditions. In summary, the bleeding rates associated with different NOACs in real-world patients vary from 1.9% to 4.3% per year of treatment. Absolute rates depend on patient characteristics such as age. Notably, these findings on the rates of major bleeding with NOACs are comparable with the major bleeding rates reported in the pivotal randomized clinical trials.

The average atrial high-rate episodes burden is only a few hours per year, and the majority of patients with atrial high-rate episodes never receive a clinical diagnosis of atrial fibrillation

Current anticoagulation guidelines in non-valvular AF are supported by studies in patients with ECG-documented AF episodes, whether symptomatic or not. Clinical diagnosis of AF in patients with AHRE was evaluated more than 10 years ago in the Ancillary MOST substudy, performed in 312 patients included in the MOST study. The population was heterogeneous, and patients with previously documented AF were not excluded. Selected patients had a pacemaker implanted due to sinus node dysfunction but were in sinus rhythm at randomization, and the analysis was retrospective and observational. During a median follow-up of 27 months, AHREs were detected in 160 patients (51.3%). Twenty of these patients had AF history documented before AHRE detection. Of the remaining 140 patients without previous AF, 36 (25.7%) had AF documented during follow-up. Similar or lower rates of AF detection were found in the ASSERT and ASSERT II studies.

Hence, although AHRE renders detection of ECG-documented AF more likely, the majority (>75%) of patients with AHRE never develop ECG-documented AF in the subsequent years, probably due to the infrequent and short nature of AHRE episodes in most patients.

Stroke risk in atrial high-rate episode patients is lower than in patients with paroxysmal atrial fibrillation

There is a growing body of evidence on the stroke risk in patients with AHREs. In the ASSERT study, the annual thromboembolic event rate was 1.7% in patients with AHRE within 3 months after inclusion.
compared with 0.7% in patients who did not show AHRE within 3 months after inclusion. These numbers are comparable to a recent systematic review where patients with AHRE had an annual stroke rate of 1.9%, compared with 0.9% in patients without AHRE.88 Recently, a subanalysis from ASSERT focused on the longest AHRE episode found that only AHRE >24 h was associated with an increased risk of stroke compared with absence of AHRE.87 This is much lower than the stroke risk that can be expected in patients with a similar stroke risk profile and ECG documented AF. Interestingly, strokes occur equally during periods with and without AHRE in patients with AHRE suffering a stroke.89 Furthermore, the current licences of NOACs do not explicitly allow their use in patients with AHRE. Thus, also in view of the bleeding risk associated with anticoagulation, we do not know whether to use oral anticoagulation in patients with AHRE.

Summary: equipoise for oral anticoagulation in patients with atrial high-rate episode

Most modern pacemakers, defibrillators, and cardiac resynchronization devices provide automated algorithms alerting to AHRE. A growing body of clinical data supports the hypothesis that AHREs are associated with an elevated risk of developing further clinical AF and stroke, but the stroke risk is substantially lower than in patients with ECG-detected AF, most likely due to the very rare and short nature of AHRE episodes.86 In view of the small but substantial risk of major bleeding in patients treated with oral anticoagulants, including NOACs, there is currently no justification for oral anticoagulation in patients with AHRE. Two ongoing studies, NOAH-AFNET 691 and ARTESIA,92 will address the key question of whether patients with AHRE benefit from oral anticoagulation. ARTESIA (Apixaban for the Reduction of Thrombo-Embolic in Patients With Device-Detected Sub-Clinical AF) aims to enroll 4000 high-risk (CHA2DS2-VASc score >3) participants with permanent pacemakers, defibrillators, or resynchronization device, and at least one AHRE episode of 6 min to 24 h duration (atrial rate >175/min if an atrial lead is present).92 Patients will be randomized to receive apixaban or aspirin. The primary efficacy outcome is ischemic stroke or systemic embolism; the primary safety outcome is major bleeds. The NOAH-AFNET 6 study (NOAC in patients with AHRE) trial is recruiting ca 3000 patients aged >65 years with one additional CHA2DS2-VASc factor and AHRE documented by CIED (>170 b.p.m. atrial rate and >6 min duration).87 These patients will be randomized to edoxaban or aspirin/placebo, depending on the indications for antplatelet therapy. The primary outcome parameter of NOAH-AFNET 6 is a composite of stroke, systemic embolism, or cardiovascular death. The results of these two trials have the potential to inform future guidance on the management of patients with atrial arrhythmias detected by implantable devices. Until these trials have reported, treatment with oral anticoagulants should be limited to rare individual decisions in patients with AHRE, but without ECG-diagnosed AF, to avoid the substantial bleeding risk on anticoagulation.

Funding

This work was largely written by voluntary contributions of time from the authors. It was partially supported by British Heart Foundation (FS/13/43/30324 to P.K.; PG/17/30/32961 to P.K.). German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, via a grant to AFNET) and by Leducq Foundation.

Conflict of interest: J.R.d.G. receives consultant or speaker fees from Atricure, Daiichi Sankyo, Bayer and Novartis. He received research funding through institution from Abbott, Boston Scientific, Medtronic, Atricure and Owner RhythmCare. A.G. receives lecture fees from Sanofi, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Medtronic, Omeicos, and Astra-Zeneca. P.K. receives research support from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation and has received honoraria from several such companies. P.K. is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). P.V. receives personal fees from Menarini International, Dean Medicus, Servier, European Society of Cardiology, Bayer and Hygeia Hospitals group. All other authors declared no conflict of interest.

References

1. Defaye P, Doumaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol 1998;21:250–5.
2. Todd D, Hernandez-Madrid A, Proclemer A, Bongioni MG, Estner H, Blomstrom-Lundqvist C et al. How are arrhythmias detected by implanted cardiac devices managed in Europe? Results of the European Heart Rhythm Association Survey. Europace 2015;17:1449–53.
3. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017;14:701–14.
4. Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M et al. Atrial high-rate episodes and stroke prevention. Europace 2017;19:569–79.
5. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaromanen S, Mairesse GH et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241–6.
6. Gilles AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol 2002;13:542–7.
7. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107:1614–9.
8. Tse HF, Lau CP. Prevalence and clinical implications of atrial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome. Heart 2005;91:362–4.
9. Capucchi A, Santini M, Padelleti L, Gulizia M, Botto G, Boriani G et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005;46:1913–20.
10. Cheung JW, Kesting RJ, Stein KM, Markowitz SM, Iwai S, Shah BK et al. Newly detected atrial fibrillation following dual chamber pacemaker implantation. J Cardiovasc Electrophysiol 2006;17:1323–8.
11. Orlov MV, Glaz K, Araghich-Nikman M, Sherfesee L, Sahr D, Hettrick DA et al. Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol 2003;26:104–11.
12. Mittal S, Stein K, Gilliam FR 3rd, Kraus SM, Meyer TE, Christman SA. Frequency, duration, and predictors of newly-diagnosed atrial fibrillation following dual-chamber pacemaker implantation in patients without a previous history of atrial fibrillation. Am J Cardiol 2008;102:450–3.
13. Healey JS, Martin JL, Duncan A, Connolly SJ, Ha AH, Morillo CA et al. Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol 2013;29:224–8.
60. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012;76:2289–304.
61. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–70.
62. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Euro Heart Survey 2010;137:263–72.
63. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATTRA study stroke risk score. J Am Heart Assoc 2013;2:e000250.
64. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049–56.
65. Vanasse T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 5653 aspirin-treated patients in ACTIVE-A and AVERRIDES. Eur Heart J 2015;36:281–7a.
66. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967–75.
67. Lip GY, Frison L, Grind M. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008;264:50–61.
68. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:2464–71.
69. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
70. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J 2016;37:1591–602.
71. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444–51.
72. Hart RG, Sharma M, Mundli H, Kasper SE, BangdwoIa SI, Berkowitz SD et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2013;369:2191–201.
73. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchida Y et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2011;365:1906–17.
74. Markus HS, Hayter E, Levi C, Feldman A, Venable G, Norris J. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol 2015;14:361–7.
75. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–16.
76. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–69.
77. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018;379:1332–42.
78. Group ES, Halles P, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115–24.
79. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.
80. Graham DJ, Reichman ME, Wenercke M, Zhang R, Southworth MR, Lenerson M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157–64.
81. Kirchhof P, Radaideh G, Kim YH, Laras F, Haas S, Amarenco P et al. Global prospective safety analysis of rivaroxaban. J Am Coll Cardiol 2018;72:141–53.
82. Staerk L, Fosbol EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 2017;38:907–15.
83. Halvorsen S, Ghanima W, Fridt Tveit E, Hoekx C, Falck P, Solli O et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017;3:28–36.
84. Kirchhof P, Benussi S, Kotekha D, Ahlsson A, Atar D, Casadei B et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;38:1609–78.
85. Kirchhof P, Curtis AB, Skanes AC, Gilis AM, Samuel Wann L, John Camm A. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471–4.
86. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002;346:584–62.
87. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASIERT. Eur Heart J 2017;38:1339–44.
88. Majahan P, Perera T, Elliott AD, Towner MD, Kumar S, Munwar DA et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J 2018;39:1407–15.
89. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094–9.
90. Gorenek B, Baz J, Bonani G, Chen SA, Dagres N, Glotzer TV et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrostimulación (SOLEACE). Europace 2017;19:1556–78.
91. Kirchhof P, Blank BF, Calvert M, Camm AJ, Chiuversakis G, Diener HC et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with atrial high rate episodes (NOAA-APNET 6) trial. Am Heart J 2017;170:12–18.
92. Lopes RD, Alings M, Connolly SJ, Berech H, Granger CB, Mazuecos JB et al. Rationale and design of the Axipaban for the Reduction of Thrombo-Embolic in Patients With Device-Detected Sub-Atrial fibrillation (ARTIESA) trial. Am Heart J 2017;189:137–45.